News Agency
Men's Weekly

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

  • Written by PR Newswire

SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001...

Read more: Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib)...

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion